NANOVIRICIDES, INC - APPLIED TO ACOREP FOR APPROVAL TO BEGIN PHASE II CLINICAL TRIAL OF NV-387 ORAL GUMMIES AS TREATMENT FOR BUNDIBUGYO EBOLAVIRUS

Reuters · 3d ago

Please log in to view news